U.S. Markets open in 8 hrs 12 mins

Synovics Pharmaceuticals, Inc. (SYVC)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.00020.0000 (0.00%)
At close: 2:32PM EDT

Synovics Pharmaceuticals, Inc.

5360 Northwest 35th Avenue
Fort Lauderdale, FL 33309
United States

Full Time Employees155

Key Executives

NameTitlePayExercisedYear Born
Mr. Jyotindra R. GangeInterim Principal Exec. Officer & DirectorN/AN/A1949
Mr. John S. CopanosVP of Bus. Devel. of Kirk Pharmaceuticals LLC232.93kN/A1971
Mr. John R. PalmerChairman of InCon Technologies Inc.& Incon International Ltd. & CEO of InCon Technologies IncN/AN/A1943
Amounts are as of December 31, 2008 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Synovics Pharmaceuticals, Inc., through its subsidiaries, engages in the development, manufacture, and commercialization of generic over-the-counter (OTC) pharmaceutical products and generic prescription drug products primarily in the United States. The company's OTC product categories include analgesics, cough, cold, antihistamines, asthma relief, and laxatives. It packages and distributes its products to chain drug stores, wholesalers, and distributors in the United States. The company was formerly known as Bionutrics Inc. and changed its name to Synovics Pharmaceuticals, Inc. in 2006. Synovics Pharmaceuticals, Inc. was founded in 1983 and is based in Fort Lauderdale, Florida. Synovics Pharmaceuticals, Inc. operates as a subsidiary of Maneesh Pharmaceuticals Limited.

Corporate Governance

Synovics Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.